Concerned over reports of impropriety, a prominent Republican senator is reportedly demanding answers from the U.S. Food and Drug Administration and the maker of Prodisc over rumors that some doctors involved in the clinical research of the synthetic spinal disk stood to gain financially from the medication's success.
A California federal court has allowed Foley & Lardner LLP to add new defenses against a pharmaceutical development company that claims it lost international rights to drug delivery technology because the law firm filed a patent application late.
DLA Piper is continuing to work toward establishing itself as a leader in the global life sciences marketplace, most recently by hiring experienced corporate attorney Bruce W. Jenett, former co-chair of the life sciences practice at Heller Ehrman LLP.
A federal judge has, for the second time, decided to reconsider a December claims construction order in Medtronic Inc.’s infringement suit against Abbott Laboratories and its cardiovascular unit over balloon catheter and stent patents.
U.S. lawmakers have called for legislation mandating full disclosure of health care industry payments to physicians, following revelations that five top orthopedic implant makers spent $230 million on payments to doctors last year.
In the wake of a rash of recent drug recalls, the U.S. Food and Drug Administration reportedly is set to keep a closer eye on the use of medicines after they have reached the market, marking a shift from its traditional focus on pre-approval monitoring of new treatments.
Apotex Corp. and Pfizer Inc. have settled all outstanding patent infringement and antitrust litigation over Pfizer's blockbuster epilepsy drug, Neurontin, which had earned the company more than $2 billion a year.
Marking a sweeping victory for AstraZeneca, a federal judge ruled Monday that a group of drugstores had failed to prove the pharmaceutical giant violated antitrust law when it put its marketing muscle behind heartburn drug Nexium instead of Prilosec as the latter's patent protection was about to lapse.
A federal jury has ordered Wyeth Pharmaceuticals Inc. to hand over $2.75 million to an Arkansas woman who accused the drugmaker of failing to warn of the increased cancer risk associated with its hormone replacement therapy.
A company that provides streaming Web video of court proceedings has asked a judge for permission to film an upcoming status hearing in the multidistrict litigation over Zyprexa, but the maker of the drug has objected to the request.
Caliper Life Sciences and AntiCancer Inc. have reached a cross-licensing deal for fluorescent imaging technology used to detect tumors, ending pending patent litigation between the bio-imaging rivals.
GlaxoSmithKline has filed a patent suit against Barr Pharmaceuticals Inc., claiming infringement of three patents covering its enlarged-prostate treatment, Avodart.
The judge overseeing Johnson & Johnson subsidiary DePuy Spine Inc.'s patent suit against Medtronic smacked the defendants with a $10 million sanction for dragging out the proceedings and choosing a defense that threatened to mislead and confuse the jury.
A federal judge has granted conditional collective action certification for a group of current and former Eli Lilly pharmaceutical representatives who are suing the company for overtime wages, claiming that their positions should not be considered exempt under the Fair Labor Standards Act.
UnitedHealth Group Incorporated proceeded Monday with its purchase of Sierra Health Services Inc. after agreeing to divest its Las Vegas area enrollees, as stipulated by the U.S. Department of Justice as an alternative to an antitrust suit.
The U.S. Supreme Court said on Monday that it will not hear a case against St. Jude Medical SC over its allegedly defective artificial heart valve, letting stand a state court’s decision to toss the case according the doctrine of regulatory preemption.
Under scrutiny from Congress, Pfizer Inc. said Monday it is withdrawing the Lipitor commercials that center on Dr. Robert Jarvik, who invented an artificial heart but is not licensed to practice medicine.
Biotechnology company Genzyme Corp. has sued Pentech Pharmaceuticals Inc. to prevent it from marketing a generic version of Hectorol, a synthetic form of Vitamin D used to treat secondary hyperparathyroidism in patients with chronic kidney disease.
In a double whammy for a Merck & Co. subsidiary, two European courts have separately knocked down the drug manufacturer’s key patent covering a generic version of its osteoporosis drug Fosamax, according to a rival maker of generic drugs.
Former Ropes & Gray LLP partner Kristopher D. Brown, who specializes in mergers and acquisitions and private equity in the life sciences and health care industries, has joined the corporate and securities group at Dechert LLP.